Point72 Asset Management
BCRX icon

Point72 Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Point72 Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
+260,917
New +$2.36M ﹤0.01% 2214
2026
Q1 		– Sell
-1,213,576
Closed -$9.47M – 3792
2025
Q4 		$9.47M Buy
1,213,576
+975,389
+410% +$7.05M 0.01% 1391
2025
Q3 		$1.81M Buy
+238,187
New +$1.98M ﹤0.01% 1480
2024
Q2 		– Sell
-1,616,244
Closed -$8.21M – 1865
2024
Q1 		$8.21M Buy
+1,616,244
New +$9.09M 0.02% 787
2023
Q4 		– Sell
-2,758,813
Closed -$19.5M – 2174
2023
Q3 		$19.5M Sell
2,758,813
-1,245,887
-31% -$8.95M 0.06% 412
2023
Q2 		$28.2M Buy
4,004,700
+3,951,200
+7,385% +$31.7M 0.08% 292
2023
Q1 		$446K Sell
53,500
-1,935,127
-97% -$18.6M ﹤0.01% 1264
2022
Q4 		$22.8M Buy
+1,988,627
New +$24.8M 0.08% 310
2022
Q3 		– Sell
-644,100
Closed -$6.82M – 1408
2022
Q2 		$6.82M Buy
+644,100
New +$6.64M 0.03% 620
2022
Q1 		– Sell
-25,272
Closed -$350K – 1175
2021
Q4 		$350K Sell
25,272
-178,641
-88% -$2.36M ﹤0.01% 984
2021
Q3 		$2.93M Buy
+203,913
New +$3.22M 0.01% 746
2021
Q1 		– Sell
-3,230,800
Closed -$24.1M – 962
2020
Q4 		$24.1M Buy
3,230,800
+2,598,200
+411% +$13.4M 0.12% 240
2020
Q3 		$2.17M Sell
632,600
-254,970
-29% -$1.09M 0.01% 699
2020
Q2 		$4.23M Sell
887,570
-2,130,562
-71% -$8.51M 0.03% 502
2020
Q1 		$6.04M Sell
3,018,132
-5,364,768
-64% -$14.8M 0.05% 361
2019
Q4 		$28.9M Buy
8,382,900
+5,122,900
+157% +$12.9M 0.15% 192
2019
Q3 		$9.34M Buy
+3,260,000
New +$10.1M 0.06% 369
2019
Q2 		– Sell
-47,453
Closed -$386K – 1336
2019
Q1 		$386K Sell
47,453
-302,547
-86% -$2.59M ﹤0.01% 891
2018
Q4 		$2.83M Buy
+350,000
New +$2.72M 0.01% 666
2018
Q1 		– Sell
-933,766
Closed -$4.58M – 942
2017
Q4 		$4.58M Buy
+933,766
New +$4.52M 0.02% 608
2015
Q3 		– Sell
-2,000
Closed -$30K – 764
2015
Q2 		$30K Buy
+2,000
New +$22.7K ﹤0.01% 695

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Point72 Asset Management's BCRX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 260,917 shares worth $2.61M. The stake represents ﹤0.01% of the portfolio and ranks #2214 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in BCRX as recently as Q4 2025.

Point72 Asset Management first reported a position in BCRX in Q2 2015 and has held it in 21 quarters since. The position peaked at $28.9M in Q4 2019. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Point72 Asset Management held 260,917 shares of BioCryst Pharmaceuticals worth $2.61M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Point72 Asset Management position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2214 holding.
  • Point72 Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 21 quarters since.
  • Point72 Asset Management's BioCryst Pharmaceuticals position peaked at $28.9M in Q4 2019.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.